FLT3 Gene

Last updated on: 28.10.2021

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

FLT3 (Fms Related Receptor Tyrosine Kinase 3) is a protein coding gene located on chromosome 13q12.2. The FLT3 gene encodes an important class III receptor tyrosine kinase that is essential for the normal functioning of the myeloid cell as well as for leukemogenesis. The activated receptor kinase phosphorylates and activates several cytoplasmic effector molecules in signaling pathways involved in apoptosis, proliferation and differentiation of hematopoietic cells in the bone marrow (Medinger M et al. 2017).

General informationThis section has been translated automatically.

Mutations of the FLT3 gene leading to constitutive activation of this receptor are detected in acute myeloid leukemia and acute lymphoblastic leukemia (Krstovski N et al. 2010). Related signaling pathways include CNTF and ERK signaling pathways. An important paralog of this gene is FLT1.

Note(s)This section has been translated automatically.

An increasing number of inhibitors against the FLT3 kinase have been developed in recent years, some of which have already been approved for the treatment of AML - one each for first-line therapy and for the relapse situation. Therefore, molecular genetic testing for the presence of FLT3 mutations is obligatory at diagnosis and relapse of AML, because patients may benefit from the use of these drugs in case of a positive result. Intensive work is being done on further FLT3 inhibitors as well as on combinations of such substances with chemotherapy or with other targeted therapeutics.

LiteratureThis section has been translated automatically.

  1. Krstovski N et al. (2010) Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature. Med Oncol 27:640-645.
  2. Medinger M et al (2017) Acute myeloid leukaemia genomics. Br J Haematol. 2017 Nov;179(4):530-542.

Last updated on: 28.10.2021